Related Experiment Video

Updated: Aug 5, 2026

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

Treatment of ovarian cancer: the state of the art

N Einhorn

    Medical Oncology and Tumor Pharmacotherapy
    |January 1, 1993
    PubMed

    Abstract:

    The state of the art in the treatment of ovarian cancer is reviewed. Development in strategies for early and advanced ovarian cancer stages as well as prospects for the future are described.

    More Related Videos

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
    10:58

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

    Published on: July 18, 2016

    An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
    05:42

    An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

    Published on: January 26, 2024

    Related Experiment Videos

    Last Updated: Aug 5, 2026

    In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
    07:46

    In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

    Published on: August 17, 2010

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
    10:58

    Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

    Published on: July 18, 2016

    An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
    05:42

    An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

    Published on: January 26, 2024

    Related Concept Videos

    Cancer Therapies02:49

    Cancer Therapies

    Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
    However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Gain of chromosome 3q is an early and consistent genetic aberration in carcinomas of the vulva.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005

    Laminin-5 gamma 2 chain as an invasivity marker for uni- and multifocal lesions in the lower anogenital tract.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2002

    Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.

    European journal of cancer (Oxford, England : 1990)·2001

    D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.

    Anti-cancer drugs·2001

    Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

    Lancet (London, England)·2001

    Long-term follow-up of the Stockholm screening study on ovarian cancer.

    Gynecologic oncology·2000

    Clinical evaluation of the CORDIS vascular access port systems: a multicenter study.

    Medical oncology and tumor pharmacotherapy·1993

    Expression of an adhesion molecule and homing in B-cell chronic lymphocytic leukaemia: I. Application of the HEV-binding assay to a clinical series.

    Medical oncology and tumor pharmacotherapy·1993

    Ultrastructural investigation of DNA in megakaryoblastic leukemia by using osmium-ammine-B: comparison with several types of leukemia.

    Medical oncology and tumor pharmacotherapy·1993

    T-lymphocyte sub-populations in orbito-ocular granulocytic sarcoma (OOGS) and acute myelocytic leukemia (AML): a preliminary study.

    Medical oncology and tumor pharmacotherapy·1993

    Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma.

    Medical oncology and tumor pharmacotherapy·1993

    The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).

    Medical oncology and tumor pharmacotherapy·1993

    TREM2+ macrophages mediate anticancer therapy-induced immune evasion in lung adenocarcinoma via the CCL5/CCL22-Treg axis.

    Frontiers in immunology·2026

    Complications of clozapine cessation in the context of chemotherapy-related neutropenia-a case report.

    Frontiers in oncology·2026

    PD-1/PD-L1 inhibitors combined with chemotherapy or as monotherapy versus chemotherapy alone or observation in triple-negative breast cancer: a systematic review and updated meta-analysis incorporating long-term survival data.

    Frontiers in immunology·2026

    Network analysis of core symptom changes in hepatocellular carcinoma survivors after transarterial chemoembolization: A longitudinal study.

    Frontiers in oncology·2026

    Co-delivery of siPD-L1 and Tat-HSPB1 by G5PBA Enhances the Efficacy of Antitumor Therapy in Clear Cell Renal Cell Carcinoma.

    Bioconjugate chemistry·2026

    A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin.

    Bioconjugate chemistry·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us